Evidence map›Paper›PMID 41907888›Full record

ArticleBioinformation2025

MSH6 and PMS2 expression in colorectal carcinoma.

Safin M, Marylilly S, Janhavi Ms

Abstract read
In one paragraph

Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Safin MDepartment of Pathology, Sree Balaji Medical College and Hospital, Chennai-44, Tamilnadu, India.
Marylilly SDepartment of Pathology, Sree Balaji Medical College and Hospital, Chennai-44, Tamilnadu, India.
Janhavi MsDepartment of Pathology, Sree Balaji Medical College and Hospital, Chennai-44, Tamilnadu, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microsatellite instability (MSI) is a key feature in colorectal carcinomas (CRCs), but its role in diagnosis and prognosis, particularly through immunohistochemical markers like MSH6 and PMS2, remains underexplored. Conducted at Sree Balaji Medical College and Hospital, 50 histologically confirmed CRC samples were analyzed. Combined loss of MSH6 and PMS2 (MSI-H) was found in 30% of cases, particularly in poorly differentiated tumors, T3 stage tumors, stage II and III cancers, and node-positive groups. Thus, understanding of microsatellite instability (MSI) detection in colorectal carcinomas (CRCs) using immune histochemical markers MSH6 and PMS2, improving diagnostic and prognostic approaches for CRC.

Indexed as

colorectal carcinomaimmunohistochemistrymicrosatellite instabilityMSH6PMS2

Identifiers

PMID41907888
PMCPMC13018393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.